5 September 2014
EMA/COMP/396320/2014 Rev. 1
Committee for Orphan Medicinal Products (COMP)

Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation

July 2014

The Committee for Orphan Medicinal Products held its 158th plenary meeting on 8-10 July 2014.

Orphan medicinal product designation

Positive opinions

The COMP adopted 27 positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission (EC):

1. Opinions adopted at the second COMP discussion, following the sponsor's response to the COMP list of questions:

- (3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate for treatment of Fabry disease, Genzyme Europe BV
- 17α,21-dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione for treatment of Duchenne muscular dystrophy, NDA Group AB
- Gevokizumab for treatment of Schnitzler syndrome, Les Laboratoires Servier
- Lumacaftor and ivacaftor fixed-dose combination for treatment of cystic fibrosis, Vertex Pharmaceuticals (U.K.) Limited
- Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin for treatment of congenital factor VII deficiency, Richardson Associates Regulatory Affairs Ltd
- Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin for treatment of haemophilia A, Richardson Associates Regulatory Affairs Ltd

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

- Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin for treatment of haemophilia B, Richardson Associates Regulatory Affairs Ltd
- Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain for treatment of myelodysplastic syndromes, IDEA Innovative Drug European Associates Limited
- Recombinant human apolipoprotein A-I in a complex with phospholipids for treatment of apolipoprotein A-I deficiency, Cerenis Therapeutics Holding SA
- Recombinant human apolipoprotein A-I in a complex with phospholipids for treatment of ATP-binding cassette transporter A1 deficiency, Cerenis Therapeutics Holding SA
- Retinol for prevention of bronchopulmonary dysplasia, Dr Philipp Heinrich Novak
- Sodium ascorbate and menadione sodium bisulfite for treatment of autosomal dominant polycystic liver disease, JJGConsultancy Ltd
- Ulinastatin for treatment of acute pancreatitis, BSV BioScience GmbH

2. Opinions adopted at the first COMP discussion:

- 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide for treatment of small cell lung cancer, DualTpharma B.V.
- 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid for treatment of acute myeloid leukaemia, Roche Registration Limited
- Adeno-associated viral vector serotype 8 containing the human *UGT1A1* gene for treatment of Crigler-Najjar syndrome, Fondazione Telethon
- Humanised IgG1 monoclonal antibody against human KIR3DL2 for treatment of cutaneous T-cell lymphoma, Innate Pharma S.A.
- Lentiviral vector containing the human liver and erythroid pyruvate kinase (*PKLR*) gene for treatment of pyruvate kinase deficiency, Centro de Investigación Biomédica en Red (CIBER)
- Macromolecular conjugate of heparin sodium on a polymer backbone for prevention of ischaemia reperfusion injury associated with solid organ transplantation, Corline Systems AB
- Obinutuzumab for treatment of diffuse large B-cell lymphoma, Roche Registration Limited
- Recombinant human diamine oxidase for treatment of mastocytosis, Medical University of Vienna
- S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide) for treatment of paroxysmal nocturnal haemoglobinuria, Amyndas Pharmaceuticals S.A.
- Variant of recombinant human fibroblast growth factor 19 for treatment of primary biliary cirrhosis, Diamond BioPharm Limited
- Vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human *TYMP* gene under the control of the human

thyroxine binding globulin promoter for treatment of mitochondrial neurogastrointestinal encephalomyopathy, Vall d'Hebron Insitute of Research

- (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide for treatment of diffuse large B-cell lymphoma, Clinipace GmbH
- (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide for treatment of acute myeloid leukaemia, Clinipace GmbH
- [5-amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone for treatment of pancreatic cancer, Synovo GmbH

Revision on the COMP opinion adopted via written procedure:

- Adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene for treatment of catecholaminergic polymorphic ventricular tachycardia, Fondazione Salvatore Maugeri Clinica del Lavoro e della Riabilitazione

Public summaries of opinions will be available on the EMA website following adoption of the respective decisions on orphan designation[1] by the European Commission.

Negative opinion

The COMP adopted 1 negative opinion recommending the refusal of the orphan medicinal product designation for a product for treatment of autosomal dominant polycystic kidney disease. The sponsor was informed about the possibility to appeal.

Lists of questions

The COMP adopted 15 lists of questions on initial applications. These applications will be discussed again at the next COMP meeting prior to the adoption of an opinion.

Oral hearings

20 oral hearings took place.

Withdrawals of applications for orphan medicinal product designation

The COMP noted that 8 applications for orphan medicinal product designation were withdrawn.

Detailed information on the orphan designation procedures

An overview of orphan designation procedures since 2000 is provided in Annex 1.

The list of medicinal products for which decisions on orphan designation have been given by the European Commission since the last COMP meeting is provided in Annex 2.

[1] Details of all orphan designations granted to date by the European Commission are entered in the EU Register of Orphan Medicinal Products

Applications for marketing authorisation for orphan medicinal products

Details of those designated orphan medicinal products that have been subject of a new European Union (EU) marketing authorisation application through the centralised procedure since the last COMP plenary meeting are provided in Annex 3.

Details on the authorised orphan medicinal products can be found on the EMA website.

Other matters

The main topics addressed during the meeting related to:

- Protocol assistance advice

Upcoming meetings

- The 159th meeting of the COMP will be held on 2-4 September 2014

Note

This monthly report, together with other information on the work of the European Medicines Agency, can be found on the EMA website: www.ema.europa.eu

Contact our press officer

Monika Benstetter

Tel. +44 (0)20 3660 8427, E-mail: press@ema.europa.eu

Annex 1

Overview for orphan medicinal product designation procedure since 2000

Year	Applications submitted	Applications discussed in reporting year	Positive COMP opinions	Applications withdrawn	Final negative COMP opinions	EC designations	Orphan medicinal products[2] authorised	Orphan designations included in authorised therapeutic indication
2014	140	134	99 (74%)	33 (25%)	1[5] (1%)	69	8	8
2013	201	197	136 (69%)	60 (30%)	1 (1%)	136	7	8
2012	197	192	139 (72%)	52 (27%)	1 (1%)	148	10	12
2011	166	158	111 (70%)	45 (29%)	2 (1%)	107	5	5
2010	174	176	123 (70%)	51 (29%)	2 (1%)	128	4	4
2009	164	136	113 (83%)	23 (17%)	0[3] (0%)	106	9	9
2008	119	118	86 (73%)	31 (26%)	1 (1%)	73	6	7
2007	125	117	97 (83%)	19 (16%)	1 (1%)	98	13	13
2006	104	103	81 (79%)	20 (19%)	2 (2%)	80	9	11
2005	118	118	88 (75%)	30 (25%)	0 (0%)	88	4	4
2004	108	101	75 (74%)	22 (22%)	4 (4%)	73	6	6
2003	87	96	54 (56%)	41 (43%)	1 (1%)	55	5	5
2002	80	75	43 (57%)	30 (40%)	2[4] (3%)	49	4	4
2001	83	90	62[4] (70%)	27 (29%)	1 (1%)	64	3	3
2000	72	32	26 (81%)	6 (19%)	0 (0%)	14	0	0
Total	**1938**	**1843**	**1333 (72%)**	**490 (27%)**	**19 (1%)**	**1288**	**93**	**99**

[2] Number of authorised orphan medicinal products may cover more than one orphan designation
[3] Negative opinion adopted in 2009 was revised and finalised in 2010, therefore it is not included in 2009 listing
[4] Following a quality assurance exercise it was identified that this figure needed correction
[5] One negative opinion removed, the sponsor has the possibility to appeal

Annex 2

Medicinal products granted a European Union designation as orphan medicinal product by the European Commission since the June 2014 COMP monthly report

Active substance	Orphan indication	Sponsor	COMP opinion date	EC designation date
1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxamide	Treatment of cystic fibrosis	Vertex Pharmaceuticals (U.K.) Limited	14 May 2014	4 July 2014
Adeno-associated viral vector serotype 2 containing the human *REP1* gene	Treatment of choroideraemia	NightstaRx Ltd.	14 May 2014	4 July 2014
Afamelanotide	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Clinuvel UK Limited	14 May 2014	4 July 2014
Beloranib	Treatment of Prader-Willi syndrome	Dr Ulrich Granzer	14 May 2014	4 July 2014
Humanised Fc engineered monoclonal antibody against CD19	Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma	MorphoSys AG	14 May 2014	4 July 2014
Isavuconazonium sulfate	Treatment of invasive aspergillosis	Basilea Medical Ltd	14 May 2014	4 July 2014
Mixture of two adeno-associated viral vectors of serotype 8 containing the 5'-half sequence of human *MYO7A* gene and the 3'-half sequence of human *MYO7A* gene	Treatment of Usher syndrome	Fondazione Telethon	14 May 2014	4 July 2014
Mixture of two adeno-associated viral vectors of serotype 8 containing the 5'-half sequence of human *ABCA4* gene and the 3'-half sequence of human *ABCA4* gene	Treatment of Stargardt's disease	Fondazione Telethon	14 May 2014	4 July 2014

Active substance	Orphan indication	Sponsor	COMP opinion date	EC designation date
Norursodeoxycholic acid	Treatment of primary sclerosing cholangitis	Dr Falk Pharma GmbH	14 May 2014	4 July 2014
Recombinant human alpha-1-microglobulin	Treatment of pre-eclampsia	A1M Pharma AB	14 May 2014	4 July 2014

Annex 3

Designated orphan medicinal products that have been subject of a new European Union marketing authorisation application under the centralised procedure since the June 2014 COMP monthly report

Active substance	Designated orphan indication	Sponsor/applicant	EU designation number
1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride	Treatment of narcolepsy	Bioprojet	EU/3/07/459
Idebenone	Treatment of Leber's hereditary optic neuropathy	Santhera Pharmaceuticals (Deutschland) GmbH	EU/3/07/434
Nintedanib	Treatment of idiopathic pulmonary fibrosis	Boehringer Ingelheim International GmbH	EU/3/13/1123
Panobinostat	Treatment of multiple myeloma	Novartis Europharm Limited	EU/3/12/1063
Ruxolitinib	Treatment of polycythaemia vera	Novartis Europharm Limited	EU/3/14/1244
Tasimelteon	Treatment of non-24-hour sleep-wake disorder in blind people with no light perception	Vanda Pharmaceuticals Limited	EU/3/10/841